Anika Therapeutics, Inc. ANIK revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Anika Therapeutics, Inc. reported revenue across 2 products and services; the largest, OEM Channel, was $64.4M, 57.1% of the filed sum (-17.2% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- OEM Channel$64.4M57.1%-17.2% yoy
- Commercial Channel$48.4M42.9%+14.9% yoy
Members sum to the consolidated $113M for this period.
- United States$70.1M62.1%-15.0% yoy
- Europe$22.2M19.7%+14.5% yoy
- Other Location$20.5M18.2%+13.8% yoy
Members sum to the consolidated $113M for this period.
- OEM Channel$18.7M57.4%no prior
- Commercial Channel$13.9M42.6%no prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.